Skip to content

Osmidrosis treatment with percutaneous ethanol injection

Clinical effect of percutaneous ethanol injection in the treatment of osmidrosis

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014122420426N1
Enrollment
60
Registered
2015-04-09
Start date
2014-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osmidrosis. Apocrine sweat disorders

Interventions

Intervention 1: 30 Patients ranged in age from 12 to 35 years in case group were treated with percutaneous ethanol injection well. The injection procedure was carried out in an outpatient basis. Pati
Treatment - Other
Placebo
30 Patients ranged in age from 12 to 35 years in case group were treated with percutaneous ethanol injection well. The injection procedure was carried out in an outpatient basis. Patients were placed
30 Patients ranged in age from 12 to 35 year in control group as placebo were treated with percutaneous saline injection well. The injection procedure was carried out in an outpatientbasis. Patients

Sponsors

Vice Chancellor foer research of Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: having the complaint osmidrosis; age between 12-35 years old; both genders; willingness for participation in the study and signing the consent form. Exclusion criteria: pregnant or breast-feeding women; active infection at the axilla.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Osmidrosis. Timepoint: after ten months of injection. Method of measurement: starch-iodine test , visual analog scale(VAS).

Secondary

MeasureTime frame
Patients satisfaction. Timepoint: At base line – at the end of the study. Method of measurement: visual analog scale (VAS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Masoom Shahbazi

Skin disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Ira

masoom_shahbazi@med.mui.ac.ir+98 31 3626 9683

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026